Evidence map›Paper›PMID 38016997›Full record

ArticleScientific reports2023

Proteomic analyses identify HK1 and ATP5A to be overexpressed in distant metastases of lung adenocarcinomas compared to matched primary tumors.

Helen Pasternack, Mirjam Polzer, Timo Gemoll, Christiane Kümpers, Thorben Sauer, Pamela Lazar-Karsten, Sofie Hinrichs, Sabine Bohnet, Sven Perner, Franz Friedrich Dressler and 1 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Translational cancer research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Helen Pasternack *Institute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Mirjam Polzer *Institute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Timo GemollSection for Translational Surgical Oncology and Biobanking, Department of Surgery, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Christiane KümpersInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Thorben SauerSection for Translational Surgical Oncology and Biobanking, Department of Surgery, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Pamela Lazar-KarstenInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Sofie HinrichsInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Sabine BohnetDepartment of Pulmonology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Sven PernerInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Franz Friedrich Dressler *Institute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Jutta Kirfel *Institute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. jutta.kirfel@uksh.de.
University Hospital Schleswig-Holstein · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide with lung adenocarcinoma (LUAD) being the most common type. Genomic studies of LUAD have advanced our understanding of its tumor biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD are still insufficiently explored. The prognosis for lung cancer patients is still mostly determined by the stage of disease at the time of diagnosis. Focusing on late-stage metastatic LUAD with poor prognosis, we compared the proteomic profiles of primary tumors and matched distant metastases to identify relevant and potentially druggable differences. We performed high-performance liquid chromatography (HPLC) and electrospray ionization tandem mass spectrometry (ESI-MS/MS) on a total of 38 FFPE (formalin-fixed and paraffin-embedded) samples. Using differential expression analysis and unsupervised clustering we identified several proteins that were differentially regulated in metastases compared to matched primary tumors. Selected proteins (HK1, ATP5A, SRI and ARHGDIB) were subjected to validation by immunoblotting. Thereby, significant differential expression could be confirmed for HK1 and ATP5A, both upregulated in metastases compared to matched primary tumors. Our findings give a better understanding of tumor progression and metastatic spreads in LUAD but also demonstrate considerable inter-individual heterogeneity on the proteomic level.

Indexed as

Adenocarcinoma of LungLung NeoplasmsHexokinaseHumansMitochondrial Proton-Translocating ATPasesPrognosisProteinsProteomicsrho Guanine Nucleotide Dissociation Inhibitor betaTandem Mass SpectrometryARHGDIB protein, humanATP5F1A protein, humanHexokinaseHK1 protein, humanMitochondrial Proton-Translocating ATPasesProteinsrho Guanine Nucleotide Dissociation Inhibitor beta

Identifiers

PMID38016997
PMCPMC10684588
OpenAlexW4389087466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.